Combined inhibition of HMGCoA reductase and mitochondrial complex I induces tumor regression of BRAF inhibitor-resistant melanomas
ConclusionsSTN and other clinically approved HMGCRi could be promising combinatorial agents for improving the efficacy of ETC inhibitors like IACS in BRAFi-resistant melanomas.
Source: Cancer and Metabolism - Category: Cancer & Oncology Source Type: research
More News: Atorvastatin Calcium | Cancer | Cancer & Oncology | Diets | High Fat | Lipitor | Melanoma | Mitochondrial Disease | Nutrition | Skin Cancer | Statin Therapy | Study | Zivast